OWL Metabolomics

Derio, Spain

Biotech PharmaTech Precision Medicine/Diagnostics

OWL Metabolomics is a biotechnology company with the mission to identify biomarkers and therapeutic targets in the field of high prevalence diseases. The company is focused in the area of human health, with pioneering applications in the international scientific arena, and its goal is to identify, validate, patent and commercialize diagnosis and/or prognosis systems, as well as therapeutic targets. Its technological platform offers metabolomics and lipidomics services to Pharma, Biotech companies, Research Centers and Food Companies. To consolidate the developments of OWL as a technology-based company, an innovative line of development has been developed, Metabolomics, which allows opening diagnostics to the massive identification of specific biomarkers for a given pathology. Currently there are two business lines: In vitro serum based Non Alcoholic Fatty Liver Disease (NAFLD) diagnosis test. Metabolomics and lipidomics services to pharmaceutical, biotechnology companies, research centers and food industries in key areas such as biomarkers discovery, clinical studies, diagnostics, toxicology, companion diagnostics development and food biomarkers.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out OWL Metabolomics on @MedStartr Today #AllTherapeuticAreas #Biotech #PharmaTech #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/wf3mHuTduyQ

Get Involved in OWL Metabolomics

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2004
Website: www.rubiometabolomics.com/

Disease Areas

All Therapeutic Areas

Technologies

MetabolomicsBiomarkersTarget DiscoveryPlatform

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of OWL Metabolomics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.